Track topics on Twitter Track topics that are important to you
Shire said today it agreed to sell its oncology business to Servier for $2.4 billion, in a deal that advances the buyer’s goal of expanding in cancer treatments—and has led to conflicting speculation about whether Shire would accept a takeover offer from would-be suitor Takeda Pharmaceutical should such a bid emerge later this month. Shire's oncology business includes two marketed treatments: Oncaspar ® (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. rights to Onivyde ® (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL and early stage immuno-oncology pipeline collaborations. Shire’s Oncology business finished 2017 generating $261.7 million in product sales, up 22% from 2016—yet still just 3.7% of Shire’s total $6.988 billion in product sales last ...
Original Article: Servier to Acquire Shire's Oncology Business for $2.4BNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...